Archive

DOJ Catch of the Week -- Mylan

Posted 08/18/17

By the C|C Whistleblower Lawyer Team This week's Department of Justice "Catch of the Week" goes to Mylan Inc. and Mylan Specialty L.P. Yesterday, the pharmaceutical companies agreed to pay $465 million to settle charges they violated the False Claims Act by purposely misclassifying EpiPen as a generic drug to avoid paying higher Medicaid rebates. In announcing the settlement, the government stressed its "unwavering...

Tagged in: Catch of the Week, Drug and DME Pricing, FCA Federal, Medicaid, Pharma Fraud, Whistleblower Eligibility, Whistleblower Rewards,

Martin Shkreli is Found Guilty of Fraud

Posted 08/7/17

By the C|C Whistleblower Lawyer Team A recent New York Times story details the reaction to a federal jury finding Martin Shkreli guilty on three counts of fraud. Shkreli faces up to twenty years in prison for each of the first two counts and five years in prison on the final count with sentencing pending. The jury spent five days deliberating before coming to its three guilty verdicts and acquitting Shkreli on five...

Tagged in: Pharma Fraud,

Celgene to Pay $280M to Resolve Fraud Allegations

Posted 07/26/17

By the C|C Whistleblower Lawyer Team Pharmaceutical manufacturer Celgene Corp. agreed to pay $280 million to settle claims that it illegally promoted two cancer drugs, Thalomid and Revlimid, for unapproved uses. The case was filed by a former Celgene sales representative under the False Claims Act, which allows individuals to sue to recover government dollars and share in any recovery. The New York Times reports...

Tagged in: Anti-Kickback and Stark, FCA Federal, FCA State, Healthcare Fraud, Medicaid, Medicare, Off-Label and Unapproved Use, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Ninth Circuit Finds Materiality in the Face of Continued Government Payment

Posted 07/14/17

By Rosie Dawn Griffin Earlier this month, the U.S. Court of Appeals for the Ninth Circuit revived United States ex rel. Campie v. Gilead Scis., a False Claims Act (FCA) suit against pharmaceutical giant Gilead Sciences and, in doing so, provided the qui tam bar with additional guidance on how the lower courts will interpret the Supreme Court’s emphasis on materiality in Universal Health Services, Inc. v....

Tagged in: FCA Federal, FCA Materiality, FDA Fraud, Other Government Health Programs, Pharma Fraud, Whistleblower Case,

U.S. Charges 412, Including Doctors, in $1.3 Billion Health Fraud

Posted 07/14/17

By the C|C Whistleblower Lawyer Team Hundreds of people nationwide, including dozens of doctors, have been charged in health care fraud prosecutions, accused of collectively defrauding the government of $1.3 billion. Nearly one-third of the 412 charged were accused of opioid-related crimes. The health care providers, about 50 of them doctors, billed Medicare and Medicaid for drugs that were never purchased;...

Tagged in: Healthcare Fraud, Pharma Fraud,

Fraudster of the Week -- "Pharma Bro" Martin Shkreli

Posted 06/30/17

By the C|C Whistleblower Lawyer Team On Wednesday, opening statements were delivered in the trial of Martin Shkreli, the “pharma bro” who is best known for his fiftyfold price increase of the lifesaving HIV/AIDS drug Daraprim while CEO of Turing Pharmaceuticals. Shkreli is being tried, however, on several counts of securities and wire fraud dating from his time running the hedge funds MSMB Capital and MSMB...

Tagged in: Catch of the Week, Pharma Fraud,

Pharmacy Charged with Defrauding United States Over Distribution of Under and Over Potent Drugs

Posted 06/23/17

By the C|C Whistleblower Lawyer Team The owner and director of compliance of an Indiana compounding pharmacy were charged criminally in connection with their distribution of over- and under-potent drugs, and defrauding the United States by interfering with and obstructing the lawful functions of the FDA. Paul J. Elmer, 64, of Fishers, Indiana, and Caprice R. Bearden, 62, of Carmel, Indiana, were charged in a...

Tagged in: Compounding Pharmacy Fraud,

Eighth Circuit Rules That Public Disclosure Bar Applies in Drug Price Inflation Suit

Posted 05/31/17

Early this month, the U.S. Court of Appeals for the Eighth Circuit declined to revive a whistleblower’s False Claims Act (FCA) suit, ruling that prior litigation and government reports triggered the statutory public disclosure bar, even though the public disclosures at issue did not mention the defendants in the case. The case, United States ex rel. Lager v. CSL Behring. LLC, concerned fraud in the prescription drug...

Tagged in: Court Decision, FCA Federal, Pharma Fraud, Public Disclosure and Public Information,

Fraudster of the Week -- Monarch Medical Group

Posted 04/28/17

Last week, California state prosecutors charged 26 individuals, including 21 physicians and 2 pharmacists, in connection with a kickback scheme orchestrated by Tanya and Christopher King, the owners of a practice management company called Monarch Medical Group and other related companies. If convicted, the involved physicians could face up to 25 years in prison and the pharmacists could face up to 28 years. ...

Tagged in: Catch of the Week, Compounding Pharmacy Fraud, Pharma Fraud, Private Insurance Whistleblower Reward Programs, Provider Fraud,

Walgreens Settles Whistleblower Suit over Alleged Medi-Cal Fraud

Posted 04/21/17

By the C|C Whistleblower Lawyer Team Illinois-based drugstore giant Walgreens, with roughly 630 stores in California, agreed to pay $9.86 million to resolve allegations it violated the False Claims Act by knowingly submitting claims to California’s Medi-Cal program not supported by applicable diagnosis and documentation requirements. The Medi-Cal program, administered by the California Department of Health Care...

Tagged in: FCA Federal, Lack of Medical Necessity, Medicaid, Pharma Fraud, Whistleblower Case, Whistleblower Rewards,

Contact

Click here for a confidential contact or call:

DOJ Catch of the Week -- Mylan

Martin Shkreli is Found Guilty of Fraud

Celgene to Pay $280M to Resolve Fraud Allegations

Ninth Circuit Finds Materiality in the Face of Continued Government Payment

U.S. Charges 412, Including Doctors, in $1.3 Billion Health Fraud

Fraudster of the Week -- "Pharma Bro" Martin Shkreli

Pharmacy Charged with Defrauding United States Over Distribution of Under and Over Potent Drugs

Eighth Circuit Rules That Public Disclosure Bar Applies in Drug Price Inflation Suit

Fraudster of the Week -- Monarch Medical Group

Walgreens Settles Whistleblower Suit over Alleged Medi-Cal Fraud

Newsletter

Subscribe to receive email updates from the Constantine Cannon blogs

Sign up for: